Abstract:Abstract: [Objective] To investigate the clinical efficacy of pamidronate in the treatment of fibrous dysplasia. [Methods] 38 patients with fibrous dysplasia treated in the Department of orthopaedics of the 960th Hospital of the PLA Joint Logistics Support Force from January 2011 to January 2021 were analyzed retrospectively. The treatment methods were intravenous pamidronate disodium. [Results] Compared with before treatment, the VAS score of patients decreased significantly P<0.05) and SF-36 score increased significantly (P<0.05) at 6 months after treatment and the last follow-up. In terms of bone metabolism indexes, C1NP and PINP decreased significantly (P<0.001), but the difference of OST was not statistically significant (P>0.05). After six months of treatment, the lesion area was refilled or reduced in 3 patients, unchanged in 32 patients and enlarged in 3 patients. At the last follow-up, the lesion area was refilled or reduced in 7 patients, unchanged in 27 patients and enlarged in 4 patients. One patient had transient fever when taking the medicine for the first time, and five patients had pathological fractures during taking the medicine. [Conclusion] Pamidronate disodium has a certain clinical effect in the treatment of bone fibrous dysplasia.It can reduce the pain and bone metabolism of patients and delay the progress of the disease.And it has few adverse reactions.